XBI ETF Analysis: Holdings, Fees, Inception, Sectors, And Portfolio Role

Investor Checklist

• Issuer and listing venue: State Street, NYSEARCA.
• Launch date and fee: Jan 31, 2006, 0.35%.
• Portfolio size and concentration: 152 holdings, with the top 10 at 15.48%.
• Primary exposure: Equity; Health; North America; Index: S&P Biotechnology Select Industry
• Best use case: Sector satellite position for investors who want targeted industry exposure instead of a broad-market fund.
• Main risk to respect: The key risk is that XBI's stated diversification may not protect investors if its dominant exposure, largest holdings, or main macro factor reverses. Current top-10 concentration is 15.48%.

XBI Investor Snapshot

XBI is State Street SPDR S&P Biotech ETF, issued by State Street. It is best understood as a satellite allocation for a specific industry view. The fund has $7.67B in AUM, charges 0.35%, holds 152 holdings, and has top-10 concentration of 15.48%. Its largest listed holdings include Revolution Medicines, Inc. (1.75%), Travere Therapeutics, Inc. (1.75%), TG Therapeutics, Inc. (1.69%).

XBI ETF Facts: Launch Date, Issuer, Fee, Assets, And Strategy

XBI is State Street SPDR S&P Biotech ETF. Issuer: State Street. Exchange: NYSEARCA. Inception: Jan 31, 2006. Expense ratio: 0.35%. AUM: $7.67B. Mandate or tracked index: S&P Biotechnology Select Industry

XBI Top Holdings And Concentration

Holdings snapshot: May 18, 2026. XBI has 152 holdings. The top 10 positions account for 15.48%, so investors should read the fund through its largest holdings first rather than assuming every ETF is equally diversified.

• $RVMD - Revolution Medicines, Inc.: 1.75%
• $TVTX - Travere Therapeutics, Inc.: 1.75%
• $TGTX - TG Therapeutics, Inc.: 1.69%
• $ALKS - Alkermes plc: 1.61%
• $ARWR - Arrowhead Pharmaceuticals, Inc.: 1.53%
• $NBIX - Neurocrine Biosciences, Inc.: 1.46%
• $MDGL - Madrigal Pharmaceuticals, Inc.: 1.46%
• $EXEL - Exelixis, Inc.: 1.44%
• $CYTK - Cytokinetics, Incorporated: 1.42%
• $KRYS - Krystal Biotech, Inc.: 1.38%

XBI Sector And Industry Exposure

XBI exposure summary: Equity; Health; North America; Index: S&P Biotechnology Select Industry. These exposures explain what investors actually own after buying the ETF. A broad fund is usually driven by sector weights and mega-cap leadership; a sector or thematic fund is driven by the industry cycle; a bond or alternative asset fund is driven by macro variables rather than company earnings.

• Health Care: 99.87%. Sector weight from the latest public ETF holdings snapshot.
• Other: 0.13%. Sector weight from the latest public ETF holdings snapshot.
• United States: 96.62%. Country weight from the latest public ETF holdings snapshot.
• United Kingdom: 1.35%. Country weight from the latest public ETF holdings snapshot.
• Switzerland: 1.13%. Country weight from the latest public ETF holdings snapshot.
• Netherlands: 0.73%. Country weight from the latest public ETF holdings snapshot.

XBI Fees, Liquidity, And Product Structure

XBI trades on NYSEARCA. The stated expense ratio is 0.35%, and current AUM is $7.67B. Lower fees matter most for long holding periods, while AUM and trading depth matter when investors place larger orders or need reliable execution during volatile sessions.

XBI Return Drivers: What Has To Go Right

The return drivers for XBI are industry earnings revisions, capital spending, valuation multiples, sector rotation, and the largest company weights. That matters because two ETFs can both look diversified but respond to very different conditions. For XBI, investors should compare price performance with the fund's dominant exposure, the largest holdings, and the macro factor behind the category.

XBI Current Market Theme

State Street SPDR S&P Biotech ETF is a Health ETF with $7.67B in AUM, 152 holdings, top-10 concentration of 15.48%, and a leading exposure to Health Care (99.87%). The largest holdings include Revolution Medicines, Inc. (1.75%), Travere Therapeutics, Inc. (1.75%), TG Therapeutics, Inc. (1.69%).

When XBI Tends To Work

XBI tends to work when industry earnings revisions, capital spending, valuation multiples, sector rotation, and the largest company weights are moving in the fund's favor.

XBI Portfolio Role: Core Holding Or Satellite Position?

Sector satellite position for investors who want targeted industry exposure instead of a broad-market fund. In practical portfolio terms, XBI should be sized according to whether it is replacing broad market exposure, adding a factor tilt, expressing a sector view, or hedging a macro risk. The more concentrated the fund, the less it should be treated as a complete portfolio by itself.

XBI Key Risks Investors Should Watch

The main risks are specific enough to check before buying, not generic ETF fine print.

• Market risk: XBI can fall with its asset class even when the fund structure works as designed.
• Concentration risk: top-10 weight is 15.48%, which is low for an ETF in this category.
• Exposure risk: the main exposure is Equity; Health; North America; Index: S&P Biotechnology Select Industry
• Fee and trading risk: expense ratio is 0.35%; investors should still check spread, volume, and premium/discount before large orders.
• Thesis risk: The key risk is that XBI's stated diversification may not protect investors if its dominant exposure, largest holdings, or main macro factor reverses. Current top-10 concentration is 15.48%.

Who XBI Is Suitable For

XBI can be useful, but the right investor depends on time horizon, existing overlap, and drawdown tolerance.

• More suitable for investors who need a satellite allocation for a specific industry view.
• More suitable for investors who understand that XBI's top holdings and sector exposures can dominate short-term returns.
• Less suitable for investors who need stable cash income unless the fund's underlying asset class is explicitly income-oriented.
• Less suitable for investors already heavily exposed to the same largest holdings or same macro factor.

XBI What To Monitor Next

XBI should be reviewed after new holdings files, major market moves, or category-specific catalysts. The most important checks are:

• Holdings as of May 18, 2026.
• AUM: $7.67B.
• Expense ratio: 0.35%.
• Top-10 weight: 15.48%.

XBI Action Reference

A useful ETF article should end with a decision framework. For XBI, the practical read is:

• Core-index investor: use as a satellite rather than a replacement for broad diversification.
• Theme investor: check whether the latest holdings still match the investment thesis.
• Risk-control investor: cap position size because sector/factor ETFs can underperform for long stretches.

XBI Bottom Line

XBI is not just a fund name. It is a package of exposures: State Street SPDR S&P Biotech ETF; issuer State Street; fee 0.35%; AUM $7.67B; 152 holdings; top-10 weight 15.48%; holdings date May 18, 2026. The investment case is strongest when the fund's largest holdings, main exposure, and category-level return drivers all point in the same direction.

Related Topics

Common Questions